Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: Results from an international observational study

BMJ Open

Volumn 2, Issue 3, 2012, Pages

  Misra, Vijay P ^a   Ehler, Edvard ^b   Zakine, Benjamin ^c   Maisonobe, Pascal ^c   Simonetta Moreau, Marion ^d  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Department of Neurology   (Czech Republic)

^c IPSEN   (France)

^d CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; AUSTRALIA; BELGIUM; CERVICAL DYSTONIA; CLINICAL PRACTICE; CZECH REPUBLIC; DYSPHAGIA; FEMALE; FRANCE; GERMANY; HUMAN; IDIOPATHIC DISEASE; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NETHERLANDS; NEUROLOGIST; OBSERVATIONAL STUDY; PORTUGAL; PROSPECTIVE STUDY; RISK; RUSSIAN FEDERATION; TREATMENT RESPONSE; UNITED KINGDOM;

EID: 84863674674     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-000881     Document Type: Article

References (22)

1. Bhidayasiri R, Tarsy D. Treatment of dystonia. Expert Rev Neurother 2006;6:863-86. (Pubitemid 43961888)
2. Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988;3:188-94.
3. Velickovic M, Benabou R, Brin MF. Cervical dystonia pathophysiology and treatment options. Drugs 2001;61:1921-43. (Pubitemid 33702490)
4. Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991;41:1088-91.
5. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5-18.
6. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005(1): CD003633.
7. Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics 2009;3:1-7.
8. Simpson DM, Blitzer A, Brashear A, et al Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-706. (Pubitemid 351644138)
9. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-91. (Pubitemid 41227144)
10. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev 2005(1): CD004315.
11. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M, eds. Therapy with Botulinum Toxin. New York: M. Dekker, 1994:211-37.
12. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-7.
13. Cano SJ, Hobart JC, Edwards M, et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006;67:2230-2. (Pubitemid 46035484)
14. Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-62.
15. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 2008;26(Suppl 1):23-42. (Pubitemid 351899265)
16. Hefter H, Kupsch A, Müngersdorf M, et al Dysport Cervical Dystonia Study Group. A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis. BMJ Open 2011;1:e000196.
17. Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009;31:463-6.
18. Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E. A 17-year experience of abobotulinumtoxinA in cervical dystonia. Int J Neurosci. Published Online First: 20 March 2012. doi:10.3109/ 00207454.2012.665971
19. Truong D, Comella C, Fernandez HH, et al Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord 2008;14:407-14.
20. Truong D, Brodsky M, Lew M, et al Global Dysport Cervical Dystonia Study Group. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316-23.
21. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol 2007;22:95-100. (Pubitemid 47249614)
22. Skogseid IM, Malt UF, Roislien J, et al. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol 2007;14:1129-37. (Pubitemid 47459746)